The Hereditary Inclusion Body Myopathy (h-IBM) drugs in development market research report provides comprehensive information on the therapeutics under development for Hereditary Inclusion Body Myopathy (h-IBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hereditary Inclusion Body Myopathy (h-IBM). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hereditary Inclusion Body Myopathy (h-IBM) and features dormant and discontinued products.
GlobalData tracks five drugs in development for Hereditary Inclusion Body Myopathy (h-IBM) by three companies/universities/institutes. The top development phase for Hereditary Inclusion Body Myopathy (h-IBM) is preclinical with three drugs in that stage. The Hereditary Inclusion Body Myopathy (h-IBM) pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hereditary Inclusion Body Myopathy (h-IBM) pipeline products market are: Orphina Biotechnology, Nobelpharma and Gradalis.
The key targets in the Hereditary Inclusion Body Myopathy (h-IBM) pipeline products market include Bifunctional UDP N Acetylglucosamine 2 Epimerase/N Acetylmannosamine Kinase (UDP GlcNAc 2 Epimerase/ManAc Kinase or UDP N Acetylglucosamine 2 Epimerase or N Acetylmannosamine Kinase or GNE or EC 3.2.1.183 or EC 2.7.1.60).
See Also:
The key mechanisms of action in the Hereditary Inclusion Body Myopathy (h-IBM) pipeline product include Bifunctional UDP N Acetylglucosamine 2 Epimerase/N Acetylmannosamine Kinase (UDP GlcNAc 2 Epimerase/ManAc Kinase or UDP N Acetylglucosamine 2 Epimerase or N Acetylmannosamine Kinase or GNE or EC 3.2.1.183 or EC 2.7.1.60) Activator with two drugs in Preclinical. The Hereditary Inclusion Body Myopathy (h-IBM) pipeline products include one routes of administration with the top ROA being Oral and three key molecule types in the Hereditary Inclusion Body Myopathy (h-IBM) pipeline products market including Gene Therapy, and Small Molecule.
Hereditary Inclusion Body Myopathy (h-IBM) overview
Hereditary inclusion body myopathy (h-IBM) is a rare, adult-onset muscle disorder. It is characterized by severe, progressive muscle weakness. Symptoms of IBM vary, but usually include progressive weakness in the muscles of the hand, forearm, thigh, and lower leg. Physical examination and medical history, blood tests to look for disease-specific enzymes or antibodies, nerve conduction studies to measure any interruptions in the nerve signal, electromyography to help rule out neurological conditions, muscle biopsy to verify the presence of inclusion bodies, and genetic testing are useful to confirm the diagnosis. Treatment options include physical and occupational therapy and speech therapy.
For a complete picture of Hereditary Inclusion Body Myopathy (h-IBM)’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
